Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

tumor response. The most common severe (Grade 3 or higher) side effects were neutropenia (20.8%), asthenia (16.7%), febrile neutropenia (12.5%), atrial fibrillation (8.3%) and hypotension (8.3%).

"These initial results are encouraging because a relatively low proportion of patients are experiencing disease progression at this time when treated with Xcytrin plus chemotherapy consistent with the synergistic effects we observed in preclinical and early clinical studies," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "Along with the activity seen in our single agent trial for second-line treatment of non-small cell lung cancer reported last month at ASCO, these data continue to support Xcytrin's potential role in this underserved cancer and further inform the design of our pivotal Phase 3 trial in this indication, which we plan to begin in the first half of 2008."

A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from NSCLC was filed with the U.S. Food and Drug Administration in April 2007.

About Non-Small Cell Lung Cancer

The American Cancer Society estimates that there will be more than 213,000 new cases of lung cancer in the United States in 2007. Lung cancer is the leading cause of cancer death, and accounts for over 160,000 deaths in the United States each year. The most common form of lung cancer, non-small cell, is incurable in advanced stages. Lung cancer frequently spreads to other body parts, including the brain.

Xcytrin in Second-Line Lung Cancer

Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress-related proteins such as thioredoxin reductase. Its multifunctiona
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/3/2015)... Israel , August 3, 2015 ... received the statistical analysis of results from a study which ... BVX-005 phase II trial which took place in 2012, provided ... exist at the time of the study- in particular the ... epidemic in the United States in ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
(Date:8/3/2015)... -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) announced ... agreement to develop and commercialize multiple prespecified and undisclosed ... company for premier antibody development and manufacturing companies in ... the terms of the agreement, Sorrento will develop and ... American, European and Japanese market. Each of the mAbs ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4
(Date:8/3/2015)... California (PRWEB) , ... August 03, 2015 , ... Did ... or Orange County looking for exceptional and affordable home care options which A-1 ... services are just a few of the credentials A-1 Home Care Agency ...
(Date:8/2/2015)... ... August 03, 2015 , ... ... attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) conference being ... are pleased for the opportunity the AHDI conference provides us to interact with ...
(Date:8/2/2015)... ... 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can prove ... afford to start a business.” Neither needs be a major obstacle. , The U.S. ... start a business and be successful. The risks of starting a business can be high ...
(Date:8/2/2015)... ... August 02, 2015 , ... Molecular biologists in New ... indicator for mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... New South Wales tested for Ki67 expression in tissue samples from 42 patients with ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
Breaking Medicine News(10 mins):Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2
... HealthDay Reporter , TUESDAY, Sept. 20 (HealthDay News) -- ... children and teens with obsessive-compulsive disorder, new research shows. ... of the Journal of the American Medical Association ... and obsessive-compulsive disorder (OCD). "[If] a child ...
... against methamphetamine and nicotine have been selected to receive ... The two scientists, Dr. Thomas Kosten, of Baylor ... the University of Connecticut, Storrs, will each receive $500,000 ... according to the National Institute on Drug Abuse (NIDA), ...
... , TUESDAY, Sept. 20 (HealthDay News) -- New research ... saved money used for diagnosis and boosted the likelihood that ... follow-up appointments. But there,s a big catch. Researchers ... to $649 on average -- compared to the usual $3,500 ...
... Health (NIH) has awarded nearly $2 million to researchers ... to develop a new class of therapeutics for treating ... project focuses on developing biomaterials capable of capturing certain ... wound sites to enhance tissue regeneration in adults. By ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, Sept. ... breast, babies seem to turn out smarter when nourished with ... two new studies indicate. The studies, done in the ... the journal Pediatrics , found that higher levels of ...
... Foundation,s Discovery Campaign, which seeks to further the growth ... announced a major corporate pledge to that initiative. St. ... Medical, has pledged $100,000 and is a "Pioneer" level ... strengthens SIR Foundation,s Discovery Campaign as it paves the ...
Cached Medicine News:Health News:Adding Psychotherapy to Meds Helps Kids With OCD 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 3Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 2Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: